Synthetic Biologics (SYN) Shares Gap Down to $1.46

Synthetic Biologics Inc (NYSEAMERICAN:SYN)’s share price gapped down before the market opened on Thursday . The stock had previously closed at $1.93, but opened at $1.46. Synthetic Biologics shares last traded at $0.90, with a volume of 4599349 shares.

A number of equities research analysts have commented on SYN shares. Zacks Investment Research upgraded shares of Synthetic Biologics from a “hold” rating to a “buy” rating and set a $3.00 price target for the company in a report on Wednesday, September 12th. HC Wainwright restated a “buy” rating and issued a $35.00 price target on shares of Synthetic Biologics in a report on Thursday, August 9th.

Synthetic Biologics (NYSEAMERICAN:SYN) last released its quarterly earnings results on Wednesday, August 8th. The company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.40) by $0.35.

A hedge fund recently raised its stake in Synthetic Biologics stock. Blair William & Co. IL boosted its position in shares of Synthetic Biologics Inc (NYSEAMERICAN:SYN) by 14.8% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,980,857 shares of the company’s stock after acquiring an additional 255,096 shares during the period. Blair William & Co. IL owned 1.54% of Synthetic Biologics worth $631,000 as of its most recent SEC filing.

Synthetic Biologics Company Profile (NYSEAMERICAN:SYN)

Synthetic Biologics, Inc, a late-stage clinical company, develops therapeutics designed to preserve the microbiome to protect and restore the health of patients. Its lead product candidates are in Phase III development, such as SYN-004 that is designed to protect the gut microbiome from the effects of commonly used intravenous (IV) beta-lactam antibiotics for the prevention of C.

See Also: What is a stock split?

Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with's FREE daily email newsletter.

Leave a Reply